Current status of liver transplantation for cholangiocarcinoma

查看全文 作　　者：Patrick [1]Twohig;Thoetchai Bee [1]Peeraphatdit;Sandeep [2]Mukherjee

机构地区：[1]Department of Internal Medicine,Division of Gastroenterology and Transplant Hepatology,University of Nebraska Medical Center,Omaha,NE 68198,United States;[2]Department of Internal Medicine,Division of Gastroenterology,Creighton University,Omaha,NE 68124,United States

出　　处：《World Journal of Gastrointestinal Surgery》索引2022年第14卷第1期,共11页

摘　　要：Cholangiocarcinoma(CCA)is the second most common liver cancer with a median survival of 12-24 mo without treatment.It is further classified based on its location into intrahepatic CCA(iCCA),perihilar CCA(pCCA),and distal CCA.Surgical resection is the mainstay of treatment,but up to 70%of these tumors are inoperable at the time of diagnosis.CCA was previously an absolute contraindication for liver transplantation(LT)due to poor outcomes primary due to early recurrent disease.However,improvement in patient selection criteria and neoadjuvant treatment protocols have improved outcomes for inoperable pCCA patients with recent studies reporting LT may improve survival in iCCA.Future advances in the treatment of CCA should include refining patient selection criteria and organ allocation for all subtypes of CCA,determining effective immunotherapies and the evolving role of personalized medicine in patients ineligible for surgical resection or LT.Our article reviews the current status of LT in CCA,along with future directions in managing patients with CCA. 关键词：Intrahepatic cholangiocarcinoma Perihilar cholangiocarcinoma Liver transplantation IMMUNOTHERAPY CHEMOTHERAPY TRANSPLANT

相关文献

参考文献（59）
引证文献（3）
耦合文献（0）

参考文献(59)

引证文献(3)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Current status of liver transplantation for cholangiocarcinoma

参考文献(59)

引证文献(3)

用户提示